Nebu-Flow develops nebulisers for respiratory drug delivery, utilizing a patented aerosol formation technology for efficient delivery of hard-to-nebulise drugs.

Nebu-Flow

Nebu~Flow is developing next generation of nebulisers to unlock delivery of next generation of inhaled drugs

Ascension Life Fund

SCVC

SIS Ventures

Foresight Williams

Nebu~Flow 

📦It's packing time! 📦 
We are getting ready for our move to a fantastic new location. Stay tuned for more updates... 🏢✨

Glasgow-based medical device firm Nebu~Flow has secured an additional £4.7 million of investment to help accelerate the next generation of inhaled drugs for patients with respiratory conditions. 

#Tech | #News | #Glasgow

Today's The Herald Scotland reports on Nebu~Flow  securing an additional £4.7 million of investment to accelerate the next generation of inhaled drugs for patients with respiratory disorders, which are the main cause of death and disability worldwide.  The company’s nebuliser platform has been developed to provide a number of advantages over existing technologies. Overall, the worldwide inhalable drug market was valued at approximately $33 billion in 2023, with the nebuliser market valued at over $1 billion.  

The funding round was led by SCVC, a leading UK-based venture capital firm that invests in early-stage deep tech spinouts, and was supported by Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund.

I am pleased to announce that Foresight Group has provided follow on investment to Nebu~Flow .

Congratulations to Elijah Nazarzadeh and the rest of the team. I look forward to continue working with you on the next stage of the journey.

I am delighted to announce Nebu~Flow ’s latest investment from a group of brilliant investors, bringing the total investment in our new category of nebulisers, transforming inhalation drug delivery, to above £8.5m. 

Thanks to all our investors with their continued support SCVC, Scottish Enterprise, Foresight Group, WAE, SIS Ventures ,Ascension Life Fund, Conduit Connect

#startup #medicaldevices #nebuliser #RNA #respiratory #inhalation

Huge congratulations to Elijah Nazarzadeh and the entire Nebu~Flow team for raising £4.7m in seed funding to optimize the next generation of inhaled drugs for patients with respiratory disorders.

The Conduit EIS Impact Fund are delighted to have backed this round alongside SCVC, Scottish Enterprise, Foresight Group, WAE, SIS Ventures , Ascension Life Fund.

We can't wait to see what's next! ✨🚀 

Read more: https://lnkd.in/eKjejhBC

#RNA #Nebluiser #inhalation

COM:NEBUFLOW

Nebu-Flow

Analysis Not Available